Pneumocystis jirovecii—from a commensal to pathogen: clinical and diagnostic review

Parasitology Research

Volumn 114, Issue 10, 2015, Pages 3577-3585

  Sokulska, Magdalena ^a   Kicia, Marta ^a   Wesołowska, Maria ^a   Hendrich, Andrzej B ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Colonization; Opportunistic infection; Pneumocystis jirovecii; Pneumocystis pneumonia

Indexed keywords

CASPOFUNGIN; CYCLOSPORIN A; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FOLIC ACID; GLUCOCORTICOID; INTERLEUKIN DERIVATIVE; LARGE SUBUNIT RIBOSOMAL RNA; LUNG SURFACTANT; RITUXIMAB; SULFAMETHOXAZOLE; THYMOCYTE ANTIBODY; TRIMETHOPRIM;

ANTIBIOTIC PROPHYLAXIS; ARTIFICIAL VENTILATION; ASYMPTOMATIC INFECTION; BACTEREMIA; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; FUNGAL COLONIZATION; FUNGICIDAL ACTIVITY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENSIVE CARE UNIT; LIFE CYCLE; MORTALITY; MULTILOCUS SEQUENCE TYPING; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN INFANT DEATH SYNDROME; SURVIVAL RATE; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; AIDS RELATED COMPLEX; COMPLICATION; GENETICS; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; PHYSIOLOGY; PNEUMOCYSTIS CARINII;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS;

EID: 84941317017     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-015-4678-6     Document Type: Review

References (67)

1. Alanio A, Desoubeaux G, Sarfati C, Hamane S, Bergeron A, Azoulay E, Molina JM, Derouin F, Menotti J (2011) Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 17:1531–1537
2. Aliouat EM, Mazars E, Dei-Cas E, Delcourt P, Billaut P, Camus D (1994) Pneumocystis cross infection experiments using SCID mice and nude rats as recipient host, showed stronghost-species specificity. J Eukaryot Microbiol 41:71S
3. Aliouat-Denis C-M, Chabé M, Demanche C, Aliouat EM, Viscogliosi E, Guillot J, Delhaes L, Dei-Cas E (2008) Pneumocystis species, co-evolution and pathogenic power. Infect Genet Evol 8:708–726
4. Alvarez-Martínez MJ, Miró JM, Valls ME et al (2006) Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis 56:153–160
5. Armstrong W, Meshnick S, Kazanjian P (2000) Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes Infect 2:61–67
6. Barry S, Johnson M (2001) Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management. HIV Med 2:123–132
7. Beard CB, Carter JL, Keely SP et al (2000) Genetic variations in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis 6:265–272
8. Bento DP, Esteves F, Matos O, Miranda AC, Ventura F, Araújo C, Mansinho K (2013) Unusual coexistence of opportunistic lung infections in a human immunodeficiency virus positive patient suffering from persistent Pneumocystis jirovecii pneumonia: a case report. Rev Port Pneumol 19:129–133
9. Borstnar S, Lindic J, Tomazic J, Kandus A, Pikelj A, Prah J, Skvarc M, Godunov U, Kovac D (2013) Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience. Transpl Proc 45:1614–1617
10. Caselli D, Petris MG, Rondelli R et al (2014) Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 164:389–392
11. De Boer MGJ, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT (2011) Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 13:559–569
12. Dęborska-Materkowska D, Kozińska-Przybył O, Mikaszewska-Sokolewicz M, Durlik M (2014) Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis—case report. Transpl Proc 46:2908–2911
13. Dimonte S, Berrilli F, D’Orazi C, D’Alfonso R, Placco F, Bordi E, Perno CF, Di Cave D (2013) Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy. Infect Genet Evol 14:68–72
14. Djawe K, Daly KR, Vargas SL, Santolaya ME, Ponce CA, Bustamante R, Koch J, Levin L, Walzer PD (2010a) Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein. Int J Infect Dis 14:e1060–1066
15. Djawe K, Huang L, Daly KR et al (2010b) Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients. PloS One 5:e14259
16. Dumoulin A, Mazars E, Seguy N, Gargallo-Viola D, Vargas S, Cailliez JC, Aliouat EM, Wakefield AE, Dei-Cas E (2000) Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 19:671–678
17. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML (1988) Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 334:519–522
18. Esteves F, Montes-Cano MA, de la Horra C, Costa MC, Calderón EJ, Antunes F, Matos O (2008) Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clin Microbiol Infect 14:356–362
19. Esteves F, Gaspar J, De Sousa B, Antunes F, Mansinho K, Matos O (2011) Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCR-single-base-extension methodology. J Clin Microbiol 49:1810–1815
20. Esteves F, Lee C-H, De Sousa B, Badura R, Seringa M, Fernandes C, Gaspar JF, Antunes F, Matos O (2014) (1 → 3) β-d-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients. Eur J Clin Microbiol Infect Dis 33:1173–1180
21. Frenkel JK (1999) Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol 46:89–92
22. From the Centers for Disease Control (1992) Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV [published erratum appears in JAMA 1992; 268: 55]. JAMA 267:2294–2296
23. Gigliotti F, Harmsen AG, Wright TW (2003) Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun 71:3852–3856
24. Gingo MR, Lucht L, Daly KR et al (2011) Serologic responses to Pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia. JAIDS 57:190–196
25. Held J, Koch MS, Reischl U, Danner T, Serr A (2010) Serum (1 → 3) β-d-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect 17:595–602
26. Kaneshiro ES, Ellis JE, Jayasimhulu K, Beach DH (1994) Evidence for the presence of “metabolic sterols” in Pneumocystis: identification and initial characterization of Pneumocystis carinii sterols. J Eukaryot Microbiol 41:78–85
27. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the Era of highly active antiretroviral therapy. Clin Infect Dis 30:5–14
28. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, Cannon M, Meschnick S (1998) Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12:873–878
29. Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian GA (1995) Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 172:595–598
30. Kim SJ, Lee J, Cho Y-J et al (2014) Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 69:88–95
31. Ko Y, Jeong B-H, Park HY, Koh W-J, Suh GY, Chung MP, Kwon OJ, Jeon K (2014) Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care 29:356–61
32. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, Andrianaki AM, Samonis G (2014) Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 20:412–416
33. Kutty G, Kovacs JA (2003) A single-copy gene encodes Kex1, a serine endoprotease of Pneumocystis jiroveci. Infect Immun 71:571–574
34. Li M-C, Lee N-Y, Lee C-C, Lee H-C, Chang C-M, Ko W-C (2014) Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 47:42–47
35. Limper AH, Thomas CF (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5:298–308
36. Limper AH, Offord KR, Smith TF, Martin WJ II (1989) Differences in the lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 140:1204–1209
37. Lobo ML, Esteves F, De Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O (2013) Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice. PloS One 8:e70619
38. Maitte C, Leterrier M, Le Pape P, Miegeville M, Morio F (2013) Multilocus sequence typing of Pneumocystis jirovecii from clinical samples: how many and which loci should be used? J Clin Microbiol 51:2843–2849
39. Matsumura Y, Ito Y, Yamamoto M, Matsushima A, Nagao M, Takakura S, Iinuma Y, Ichiyama S (2014) Pneumocystis polymerase chain reaction and blood (1 → 3)-β-d-glucan assays to predict survival with suspected Pneumocystis jirovecii pneumonia. J Infect Chemother 20:109–114
40. Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C, Miceli C, Bourée P, Richard C (2008) Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 12:R28
41. Monroy-Vaca EX, de Armas Y, Illnait-Zaragozí MT, Diaz R, Toraño G, Vega D, Álvarez-Lam I, Calderón EJ, Stensvold CR (2014) Genetic diversity of Pneumocystis jirovecii in colonized Cuban infants and toddlers. Infect Genet Evol 22:60–66
42. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM (2004) Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 48:4301–4305
43. Peterson JC, Cushion MT (2005) Pneumocystis: not just pneumonia. Curr Opin Microbiol 8:393–398
44. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A (1990) The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 322:161–165
45. Piffer L, Hughes WT, Stagno S, Woods D (1978) Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 61:35–41
46. Probst M, Ries H, Schmidt-Wieland T, Serr A (2000) Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 19:644–645
47. Rivero L, de la Horra C, Montes-Cano MA et al (2008) Pneumocystis jirovecii transmission from immunocompetent carriers to infant. Emerg Infect Dis 14:1116–1118
48. Roblot F, Godet C, Le Moal G et al (2002) Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 21:523–531
49. Roux A, Canet E, Valade S et al (2014) Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 20:1490–1497
50. Salerno D, Mushatt D, Myers L, Zhuang Y, de la Rua N, Calderon EJ, Welsh DA (2014) Serum and bal beta-d-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients. Respir Med 108:1688–1695
51. Selik RM, Starcher ET, Curran JW (1987) Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1:175–182
52. Spencer L, Ukwu M, Alexander T, Valadez K, Liu L, Kovacs A, Morris A (2009) Epidemiology of Pneumocystis colonization in families. Clin Infect Dis 46:1237–1240
53. Stapleton RD, Wang BM, Caldwell ES, Steinberg KP (2015) Causes and timing of death in patients with ARDS. Chest 128:525–532
54. Stringer JR (2002) Pneumocystis. Int J Med Microbiol 292:391–404
55. Stringer JR, Keely SP (2001) Genetics of surface antigen expression in Pneumocystis carinii. Infect Immun 69:627–639
56. Tasaka S, Kobayashi S, Yagi K, Asami T, Namkoong H, Yamasawa W, Ishii M, Hasegawa N, Betsuyaku T (2014) Serum (1 → 3) β-d-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother 20:678–681
57. Totet A, Latouche S, Lacube P, Pautard J, Jounieaux V, Raccurt C, Roux P, Nevez G (2004) Dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France. Emerg Infect Dis 10:667–673
58. Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, Cumsille F, Gigliotti F (2001) Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 32:855–861
59. Vargas SL, Ponce CA, Sanchez CA, Ulloa AV, Bustamante R, Juarez G (2003) Pregnancy and asymptomatic carriage of Pneumocystis jiroveci. Emerg Infect Dis 9:605–606
60. Vargas SL, Ponce CA, Gálvez P, Ibarra C, Haas EA, Chadwick AE, Krous HF (2007) Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J 26:81–83
61. Vargas SL, Ponce CA, Gallo M et al (2013) Near-universal prevalence of Pneumocystis and associated increase in mucus in the lungs of infants with sudden unexpected death. Clin Infect Dis 56:171–179
62. Vogel MN, Vatlach M, Weissgerber P, Goeppert B, Claussen CD, Hetzel J, Horger M (2012) HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 81:1315–1320
63. Volpe F, Ballantine SP, Delves CJ (1993) The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase. Eur J Biochem 216:449–458
64. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF (2003) Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 187:901–908
65. Walzer PD, Schultz MG, Western KA, Robbins JF (1976) Pneumocystis carinii pneumonia and primary immune deficiency diseases. Natl Cancer Inst Monogr 43:65–74
66. Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42:780–789
67. Wu Y-S, Lin N-C, Chen L-M, Chang S-C, Wang F-D, Huang Y-C, Wu T-H, Loong C-C (2012) Extracorporeal membrane oxygenation as treatment for acute respiratory failure and subsequent pneumothorax caused by Pneumocystis jirovecii pneumonia in a kidney transplant recipient. Transpl Infect Dis 15:E5–E8